K RAS mutation is an established predictive biomarker of resistance to antiepidermal growth factor receptor (EGFR) therapy in patients with metastatic colorectal cancer. 1-4 Specifically, patients with KRAS mutations in exon 2 do not have a response to anti-EGFR therapy and may have inferior outcomes if this therapy is combined with an oxaliplatin-containing chemotherapy regimen. 2,5 More accurate selection of patients according to the genetic status of the tumor may improve the benefit-risk profile of anti-EGFR therapy.
Activating mutations in RAS (KRAS or NRAS) in addition to KRAS mutations in exon 2 have been suggested as negative predictive biomarkers for anti-EGFR therapy. This is biologically plausible on the basis of the existing biochemical and mutational data. KRAS and NRAS are closely related RAS oncogene family members, and mutations in either gene at codons 12, 13, 61, 117, and 146 result in increased levels of guanosine triphosphate-bound RAS proteins. 6, 7 In addition, colorectal tumors harbor KRAS and NRAS mutations at these codons, and mutations tend to be mutually exclusive; this suggests functional redundancy. 8 Mutations in HRAS, the third member of the RAS family, occur infrequently in colorectal cancer. 8, 9 Clinical data have also implicated RAS genes as negative predictive biomarkers. In a randomized phase 3 study of panitumumab monotherapy 10 and other studies, 11-15 most patients with metastatic colorectal-cancer tumors harboring a mutation in KRAS or NRAS did not have a response to anti-EGFR therapy.
BRAF mutations are typically exclusive of RAS mutations, and the clinical data suggest that the BRAF V600E mutation is prognostic of patient outcome with respect to survival, but not clearly predictive of treatment effects with anti-EGFR agents, in patients with metastatic colorectal cancer. [16] [17] [18] [19] Although no objective responses to panitumumab or cetuximab monotherapy have been reported in patients with metastatic colorectal cancer and BRAF mutations, 10,20 the low prevalence of such mutations makes it difficult to evaluate them as predictive biomarkers.
Previous studies of anti-EGFR therapies combined with oxaliplatin-containing regimens have shown negative outcomes in subgroups of patients with KRAS mutations in exon 2. Identification of other biomarker-defined subgroups with similar outcomes would influence the choice of therapy. 2, 5 Here, we present the results of a prospective-retrospective biomarker analysis of the treatment effect of the full spectrum of currently characterized RAS (KRAS and NRAS) and BRAF mutations on progression-free survival and overall survival in a randomized phase 3 study of panitumumab plus oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) as compared with FOLFOX4 alone in patients with previously untreated metastatic colorectal cancer.
Me thods

Study Design and Oversight
The Panitumumab Randomized Trial in Combination with Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy (PRIME) compared the efficacy and safety of panitumumab-FOLFOX4 with those of FOLFOX4 alone in the first-line treatment of patients, according to KRAS exon 2 status. The primary end point was progressionfree survival. The secondary end points included overall survival and safety. 2 The study was designed by the sponsor, Amgen, in collaboration with the first author and the study steering committee. Clinical data were collected by the investigators, and sequencing analysis was conducted by Transgenomic under the direction of the sponsor. The sponsor performed all statistical analyses. All authors vouch for the accuracy of the data and analyses and for the fidelity of this report to the protocol, which is available with the full text of this article at NEJM.org. The preliminary draft of the manuscript was written by the second author with the assistance of a medical writer who was paid by the sponsor. Subsequent drafts were revised and reviewed by all the authors. All the authors made the decision to submit the manuscript for publication.
Tumor Specimens
Banked tumor specimens that were characterized as nonmutated KRAS exon 2 on the basis of an assay for investigational use only (TheraScreen KRAS Mutation Kit, Qiagen; LightCycler, Roche) were selected for analysis. 2 DNA was extracted from formalin-fixed, paraffin-embedded tumor specimens with the use of a DNA Extraction Mini Kit (Qiagen). Specimens that contained less than 50% tumor area were macrodissected. In a few cases, DNA was extracted from stored
Mutational Analysis
Mutations in KRAS exon 3 (at codon 61) and exon 4 (at codons 117 and 146); NRAS exon 2 (at codons 12 and 13), exon 3 (at codon 61), and exon 4 (at codons 117 and 146); and BRAF exon 15 (at codon 600) were prespecified on the basis of previous studies. 7,14, 21, 22 Gene alterations that were not prespecified (e.g., KRAS and NRAS exon 3 [codon 59] mutations) were analyzed as exploratory end points. Polymerase-chain-reaction (PCR) primer sequences amplified regions up to 200 bp in length to account for the fragmented nature of DNA in formalin-fixed, paraffin-embedded specimens. Separate data sets were generated by means of bidirectional Sanger sequencing and WAVEbased Surveyor Scan Kits (Transgenomic). [23] [24] [25] [26] Double-stranded PCR amplicons were melted and cooled to form a heteroduplex-homoduplex mixture that was treated with Surveyor nuclease. The resulting DNA fragments were analyzed with the use of high-performance liquid chromatography (WAVE HS System). The formation of mutant:nonmutant heteroduplexes resulted in fragments of various sizes. The testing plan and methods were prespecified, and investigators in the testing laboratory were unaware of treatment assignments and clinical outcomes. Bidirectional Sanger sequencing and testing with WAVE-based Surveyor Scan Kits were validated according to the Clinical Laboratory Improvement Amendments of 1988.
Statistical Analysis
The statistical analysis plan was prespecified before the RAS and BRAF testing results became available. Two clinical data snapshots were used: the primary analysis (prespecified to be performed when >50% of patients with nonmutated KRAS exon 2 had died from any cause) and the updated analysis of overall survival (an exploratory analysis that was undertaken when >80% of patients in both the nonmutated and mutated KRAS exon 2 subgroups had died from any cause), which provided the most up-to-date estimate of overall survival in the PRIME study.
The primary objective of the current prospective-retrospective analysis was to evaluate the treatment effect of panitumumab-FOLFOX4 as compared with FOLFOX4 alone in patients without RAS mutations (nonmutated KRAS and NRAS exons 2, 3, and 4) and in those without RAS and BRAF mutations (nonmutated KRAS and NRAS exons 2, 3, and 4, and BRAF exon 15) in the primary-analysis population of the PRIME study. Subsequent evaluation of the treatment effect on the basis of the updated overall-survival data was similarly prespecified in the statistical analysis plan, but only the results of the overall-survival end point are reported, since data collection was limited to survival information. Patients were characterized as having RAS mutations if any predefined activating mutation in KRAS or NRAS was detected, and patients were characterized as having RAS or BRAF mutations if any predefined RAS or BRAF mutation was detected.
The hypothesis testing in this analysis was exploratory in nature. An overall 5% significance level was used to compare the treatment effect on progression-free survival and overall survival in subpopulations without RAS mutations and in subpopulations without RAS and BRAF mutations. To control the overall type 1 error rate, a sequential testing scheme was used for evaluation of the treatment effects of panitumumab on progressionfree survival among patients with nonmutated RAS and nonmutated RAS and BRAF, followed by a test of the treatment effects on overall survival among patients in the same subgroups. No hypothesis testing was conducted in the subgroups with mutations. To estimate the treatment effects of panitumumab, we used Cox proportional-hazards models stratified according to randomization factors, with all randomly assigned patients in each biomarker subgroup included in the assessment. A log-rank test stratified according to randomization factors was used to compare the treatment effects on progression-free survival and overall survival in the panitumumab-FOLFOX4 group with the treatment effects on progression-free survival and overall survival in the FOLFOX4-alone group. Sensitivity analyses, including a multivariate Cox model and propensity-score analysis, were used to confirm the primary results. Interaction tests were performed to compare the treatment effects of panitumumab between the subgroup with nonmutated RAS and the subgroup with mutated RAS and between the subgroup with nonmutated RAS and the subgroup with nonmutated KRAS in exon 2 and other RAS mutations. Multivariate Cox models were also used to explore the prognostic relevance of baseline covariates. Baseline clinical and demographic characteristics, including race or ethnic group, age, Eastern Cooperative Oncology Group (ECOG) performancestatus score (on a scale from 0 to 5, with 0 indicating no symptoms and full activity and higher scores indicating increasing levels of disability), 27 primary tumor type, and number of metastatic lesions were generally similar between patients with nonmutated RAS and those with mutated RAS and were consistent with the reported results for KRAS exon 2 in patients with metastatic colorectal-cancer tumors. 2 The rate of ascertainment of RAS and BRAF status was 89% (assessed in 1047 of 1183 patients). Of 619 patients without KRAS mutations in exon 2 who could be evaluated for BRAF, 53 (9%) had V600E mutations. Mutations in BRAF exon 15 were mutually exclusive of KRAS and NRAS mutations in patients without KRAS mutations in exon 2 who could be evaluated. The proportion of patients with each of the RAS or BRAF mutations (Table 1) was consistent with that reported in a recently published article. 21 
Efficacy According to Tumor RAS Status
At the time of the primary analysis (data-cutoff point, August 29, 2009), 54% of the patients had died. 2 In patients without KRAS mutations in exon 2 who received panitumumab-FOLFOX4, as compared with those who received FOLFOX4 alone, there was a significant improvement in progression-free survival (9.6 vs. 8.0 months, P = 0.02) and a 4.2-month improvement in overall survival, which was not significant (23.9 vs. 19.7 months, P = 0.07) ( Table 2) . In an exploratory, updated analysis of overall survival (data-cutoff point, January 24, 2013), 82% of the patients had died. On the basis of this analysis, panitumumab-FOLFOX4 was associated with a 4.4-month improvement in overall survival (23.8 months in the panitumumab-FOLFOX4 group vs. 19.4 months in the FOLFOX4-alone group, P = 0.03).
These analyses were extended to evaluate the predictive value of mutations other than KRAS mutations in exon 2. In the subgroup of patients without RAS mutations (the primary-analysis population), panitumumab-FOLFOX4, as compared with FOLFOX4 alone, was associated with a significant improvement in progression-free survival (10.1 vs. 7.9 months, P = 0.004) and a significant 5.8-month improvement in overall survival (26.0 vs. 20.2 months, P = 0.04) ( Table 2 and Fig. 1 and 2A and 2B). Consistently, significant results were observed in the exploratory, updated overall-survival analysis with respect to the magnitude of improvement with panitumumab-FOLFOX4 as compared with FOLFOX4 alone (Table 2 and Fig. 2C ).
A total of 17% of patients without KRAS mutations in exon 2 had mutations in other RAS exons. In this subgroup of 108 patients, outcomes in the primary analysis and in the exploratory updated analysis of overall survival showed that progression-free survival (Fig. S2A in the Supplementary Appendix) and overall survival ( Fig. S2B and S2C in the Supplementary Appendix) were shorter in the panitumumab-FOLFOX4 group than in the FOLFOX4-alone group, though the difference was not significant. These outcomes were consistent with those observed in the subgroup of patients with KRAS mutations in exon 2; in this subgroup, progression-free survival in the primary analysis was significantly shorter in the panitumumab-FOLFOX4 group than in the FOLFOX4-alone group (7.3 months vs. 8.8 months, P = 0.02) ( Table 2 ). In the primary analysis, interaction testing between the subgroups that did not have RAS mutations and the subgroups that did not have KRAS mutations in exon 2 but did have other RAS mutations was significant for progression-free survival (P = 0.04) but not for overall survival (P = 0.07). In the updated analysis of overall survival, which was based on a larger number of deaths from any cause, the results of interaction testing were significant (P = 0.01). These results indicate that treatment effects differed between the subgroups of patients without RAS mutations and those without KRAS mutations in exon 2 but with other RAS mutations, suggesting that RAS mutations, in addition to KRAS mutations in exon 2, were negative predictive factors (Table 2 ). In the expanded subgroup of patients with mutated RAS tumors, progression-free survival (Fig. S3A in the Supplementary Appendix) and overall survival (Fig. S3B and S3C in the Supplementary Appendix) were significantly shorter in the panitumumab-FOLFOX4 group than in the FOLFOX4-alone group in the primary analysis and in the exploratory, updated analysis of overall survival. Interaction testing for progression-free survival and overall survival was significant in all data sets, further suggesting that RAS mutations had a negative predictive value (Table 2 ). Additional efficacy results for patients with data that could not be evaluated for RAS are shown in Table S2 in the Supplementary Appendix.
The treatment effect on progression-free survival and overall survival in favor of panitumu mab-FOLFOX4 in patients with nonmutated RAS was observed across subpopulations predefined according to baseline covariates, except an ECOG performance-status score of 2 (Fig. S4 in the Supplementary Appendix).
Subsequent to the prespecified analysis, previously reported mutations in KRAS and NRAS at codon 59 (A59G and A59T) 9,28-30 were identified in seven patients. In an exploratory analysis involving this small patient population, exclusion of these mutated alleles slightly improved progression-free survival and overall survival (Table S3 and Fig. S5 in the Supplementary Appendix).
Efficacy According to Tumor BRAF Status
In the nonmutated RAS and nonmutated BRAF subgroup, panitumumab-FOLFOX4 was associated with a 1.6-month improvement in progression-free survival and a 7.4-month improvement in overall survival, as compared with FOLFOX4 alone (Table 3 ). The minor differences between FOLFOX4-panitumumab and FOLFOX4 alone in the subgroup of patients without RAS mutations but with BRAF mutations were not significant (Fig. S6 in 
Prognostic Effects of RAS and BRAF Mutation Status
The prognostic effects of RAS and BRAF mutation status were evaluated by comparing the hazard ratios for death from any cause with no mutation versus mutation within each treatment group and across groups (Fig. S7 in the Supplementary Appendix). Most hazard ratios favored nonmutated status in the panitumumab-FOLFOX4 group and were neutral in the FOLFOX4-alone group. BRAF mutations were associated with reduced overall survival among patients without KRAS mutations in exon 2 and among those with NRAS mutations in exon 3.
Safety
The incidence rates, types, and severity of adverse events among patients with nonmutated RAS in the panitumumab-FOLFOX4 group (Table 4) were similar to those previously reported in the group of patients with nonmutated KRAS exon 2 who were treated with panitumumab-FOLFOX4. 2 Treatment exposure, disease-control rates, and the proportion of patients who discontinued any study drug due to an adverse event were also similar to those previously reported. 2 The safety profile for patients with RAS mutations was similar to that reported for patients with KRAS mutations in exon 2.
No new safety signals were identified.
Discussion
Testing for KRAS exon 2 tumor mutations is currently recommended to help guide decisions regarding eligibility for anti-EGFR therapy in patients with metastatic colorectal cancer. Although KRAS testing has facilitated the selection of patients who are most likely to have a response to anti-EGFR therapy, a substantial fraction of patients do not benefit from treatment. It is hoped that further refinement of tumor-specific genetic markers will allow more accurate selection of patients who are likely to have a response to a particular treatment and prevent toxic effects in those who are unlikely to benefit. Biomarker exploration has been broadened to include EGFR pathway mutations, in addition to those in KRAS exon 2. In a retrospective biomarker analysis of a randomized phase 3 study of panitumumab monotherapy, EGFR signalingpathway genes were assessed for their predictive ability. 10 From this study, a hypothesis was generated that activating mutations in KRAS or NRAS would be predictive of nonresponse to panitumumab therapy. The current analysis, which was based on biologic plausibility and exploratory biomarker data, further assesses the hypothesis that additional activating RAS mutations predict unresponsiveness to panitumumab treatment. 7,10, 21, 28 Negative treatment effects of panitumumab-FOLFOX4 on progression-free survival and overall survival were observed among patients with tumors that did not have KRAS mutations in exon 2 but that did have other RAS mutations. In an interaction test, treatment effects were significantly worse than those in the group of patients with nonmutated RAS; this suggests that mutations in RAS, in addition to KRAS mutations in exon 2, are predictive of adverse outcomes for panitumumab-FOLFOX4 treatment. The magnitude of the treatment effect in the patients with mutated RAS was similar to that previously observed in patients with mutated KRAS exon 2 2 and further indicated that patients with tumors that harbored any activating RAS mutations did not benefit from and may have been harmed by panitumumab-FOLFOX4 treatment.
Among patients in the primary-analysis population who did not have RAS mutations, an increase in overall survival of 5.8 months was noted with the addition of panitumumab to FOLFOX4 as compared with FOLFOX4 alone. The results of the exploratory, updated analysis of overall survival were consistent with these findings. The observed incidence, types, and severity of adverse events associated with panitumumab-FOLFOX4 in the nonmutated RAS and mutated RAS subgroups were similar to the previously reported safety findings for KRAS in PRIME, 2 and no new safety signals were identified.
In the subgroup of patients without RAS and BRAF mutations, a 7.4-month increase in overall survival was observed in the panitumumab-FOLFOX4 group. As suggested previously, 17 BRAF V600E mutations appeared to confer a poor prognosis, regardless of the treatment group.
This analysis was retrospective and exploratory in nature and therefore subject to limitations. The alpha error for hypothesis testing was previously allocated to the primary analysis, 2 and RAS and BRAF status may not be representative of the intention-to-treat population from the original Two interaction tests showed a clear separation of panitumumab treatment effects between nonmutated RAS and mutated RAS as well as between nonmutated RAS and nonmutated KRAS exon 2 with other RAS mutations; the latter finding indicates the predictive value of RAS mutations other than KRAS mutations in exon 2. These results were observed across all meaningful end points and in all relevant subgroups.
In conclusion, RAS mutations, in addition to KRAS exon 2 mutations, predict a lack of response to anti-EGFR therapy in patients with metastatic colorectal cancer. Panitumumab plus oxaliplatin-containing regimens have no value in patients with metastatic colorectal cancer and mutated RAS. The benefit-risk profile of panitumumab-FOLFOX4 was improved by excluding patients with mutated RAS metastatic colorectal-cancer tumors. Pooled trials or metaanalyses of anti-EGFR therapy are needed to confirm these findings. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
We thank Shawn Lee of Amgen for writing assistance and Mark Ekdahl of Amgen for operational assistance. 
